Last reviewed · How we verify
NCT05606432: CHIME
Cardiometabolic Health Intervention Using Movement-to-Music Exercise
NA trial testing Instructor-led, one-on-one M2M exercise group in Cardiometabolic Risk Factors in Adult Wheelchair Users in 132 participants. Currently enrolling.
30 August 2027
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 132 |
| Start date | 11 September 2023 |
| Primary completion | 30 August 2027 |
| Estimated completion | 30 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Instructor-led, one-on-one M2M exercise group
- Self-guided control with pre-recorded standard exercise videos
Conditions studied
- Cardiometabolic Risk Factors in Adult Wheelchair Users — all drugs for Cardiometabolic Risk Factors in Adult Wheelchair Users →
Sponsor
University of Alabama at Birmingham
Who can join
Adults 18 to 89, any sex, with Cardiometabolic Risk Factors in Adult Wheelchair Users. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to test the benefits of a 24-week, cardio-emphasized Movement-to-Music exercise program for reversing cardiometabolic health risk factors compared to asynchronous, standard exercise programs among 132 adult wheelchair users. The targeted cardiometabolic health factors are waist circumference, triglycerides, "good" cholesterol, glucose, and blood pressure. Additionally, a 12-week follow-up phase (weeks 25-36) is included to see whether the gains are maintained.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiometabolic Health Intervention Using Music and Exercise (CHIME) Delivered via Telehealth to Wheelchair Users: Protocol for a Randomized Controlled Trial.
Kim Y, Rimmer JH, Lai B, Oster R, et al · · 2025 · PMID 39814364 · DOI 10.2196/57423
Verify or expand the search:
- PubMed search for NCT05606432
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05606432 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05606432.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing